




162162

Abstract

A novel therapeutic agent for hyperlipidemia, which is an ester compound represented by the formula (1")



(wherein

R^1 and R^2 are each hydrogen atom or optionally substituted aryl, etc.;

10 X is $-\text{COO}-$ or $-\text{CON}(R^{10})-$;

R^3 and R^4 are each hydrogen atom, $\text{C}_1\text{-C}_6$ alkyl or $\text{C}_1\text{-C}_6$ alkoxy, etc.;

R^5 , R^6 and R^7 are each hydrogen atom, $\text{C}_1\text{-C}_6$ alkyl or $\text{C}_1\text{-C}_6$ alkoxy, etc.;

15 R^8 and R^9 are each independently hydrogen atom, $\text{C}_1\text{-C}_6$ alkyl, $-\text{CON}(R^{18})(R^{19})$ or $-\text{COO}(R^{20})$, etc.;

ring A, ring B and ring C are each independently aryl or heterocycle residue, etc.;

Alk^1 and Alk^2 are each independently alkanediyl, etc.;

20 l and m are each an integer of 0 or 1 to 3) or a prodrug thereof, or a pharmaceutically acceptable salt of either.

The therapeutic agent selectively inhibits MTP in the small intestine, thus causes no such side effect as a fatty liver.



G00001